| |
TMC-114 (protease inhibitor) Expanded Access Program
|
| |
| |
Expected Initiation: Autumn 2005
Tibotec Therapeutics Expanded Access Program
1-866-889-2074 (within US) or
e-mail: TMC114-C226@i3research.com or
http://www.tibotec.com
Class Protease Inhibitor
Usual Dose TMC-114 600mg twice daily + ritonavir 100mg twice daily
Enrollment Criteria
> 18 years old
CD4+ T cell count ≦ 200 cells/mm3
--Received treatment from each of the three major classes (NNRTIs, PIs, and NRTIs) including 2 different PI-based regimens.
--Have limited or no treatment options due to virologic failure or intolerance to multiple ARV regimens.
|
|
| |
| |
|
|
|
